1. Aujeszky’s disease must be compulsorily notifiable in the Member State of origin;

2. a plan for the control and eradication of Aujeszky’s disease, fulfilling the criteria laid down in Article 9(1) of Directive 64/432/EEC, must be in place in the Member State or regions of origin under the supervision of the competent authority. Appropriate measures on pig transport and movements must be in place according to this plan for preventing a spread of disease between holdings of a different status;

3. with regard to the holding of origin of the pigs:

(a) no clinical, pathological or serological evidence of Aujeszky’s disease has been recorded in the previous 12 months in the holding in question;

(b) no clinical, pathological or serological evidence of Aujeszky’s disease has been recorded in the previous 12 months in the holdings located in an area of 5 km surrounding the holding of origin of the pigs; however, this provision shall not apply if, in these latter holdings, disease monitoring and eradication measures have been regularly applied under the supervision of the competent authority and in accordance with the eradication plan referred to in point (2), and these measures have effectively prevented any spread of disease to the holding in question;

(c) vaccination against Aujeszky’s disease has not been carried out for at least 12 months;

(d) the pigs have been subjected on at least two occasions at an interval of at least four months to a serological survey for the presence of ADV-gE or ADV-gB or ADV-gD antibody or to the whole Aujeszky’s disease virus. This survey must have shown the absence of Aujeszky’s disease and that vaccinated pigs have been free from gE antibodies;

(e) no pigs have been introduced from holdings of a lower animal health status as regards Aujeszky’s disease in the previous 12 months, unless they have been tested for Aujeszky’s disease with negative results;

4. the pigs to be moved:

(a) have not been vaccinated;

(b) have been kept isolated in accommodation approved by the competent authority, during the 30 days prior to movement, and in such a way that any risk of spreading Aujeszky’s disease to these pigs is prevented;

(c) must have lived in the holding of origin or in a holding of an equivalent status since birth, and have remained in the holding of origin for at least:

(i) 30 days, in the case of pigs intended for production;

(ii) 90 days, in the case of pigs intended for breeding;

(d) have been subjected with negative results to at least two serological tests for ADV-gB or ADV-gD or the whole Aujeszky’s disease virus, at a distance of at least 30 days between each test. However, in case of pigs less than four months old, the serological test for ADV-gE may also be used. Sampling for the last test must be performed within 15 days prior to shipment. The number of pigs tested in the isolation unit must be sufficient to detect:

(i) 2 % seroprevalence with 95 % confidence in the isolation unit in case of pigs intended for production;

(ii) 0,1 % seroprevalence with 95 % confidence in the isolation unit in case of pigs intended for breeding.

(i) in the framework of the plan referred to in point (2), a serological survey has been carried out in the holding of origin between 45 and 170 days prior to shipment, demonstrating the absence of Aujeszky’s disease antibodies and that vaccinated pigs have been free from gE antibodies;

(ii) the pigs to be moved have lived in the holding of origin since birth;

(iii) no pigs have moved on to the holding of origin while the pigs to be moved have been kept in isolation.

1. Aujeszky’s disease must be compulsorily notifiable in the Member State of origin;

2. a plan for the control and eradication of Aujeszky’s disease is in place in the Member State or regions of origin of the pigs, fulfilling the criteria laid down in Article 1(2);

3. all the pigs in question must be transported directly to the slaughterhouse of destination and either:

(a) they come from a holding which fulfils the conditions laid down in Article 1(3); or

(b) they have been vaccinated against Aujeszky’s disease at least 15 days prior to their shipment and come from a holding of origin where:

(i) in the framework of the plan referred to in point (2), Aujeszky’s disease monitoring and eradication measures have been regularly applied under the supervision of the competent authority for the previous 12 months;

(ii) they had remained for at least 30 days before dispatch and where no clinical or pathological evidence of this disease has been detected at the moment of completion of the health certificate referred to in Article 7; or

(c) they have not been vaccinated and they proceed from a holding where:

(i) in the framework of the plan referred to in point 2, Aujeszky’s disease monitoring and eradication measures have been regularly applied under the supervision of the competent authority in the previous 12 months and no clinical, pathological or serological evidence of Aujeszky’s disease has been recorded in the previous six months;

(ii) vaccination against Aujeszky’s disease and introduction of vaccinated pigs have been forbidden by the competent authority, since the holding is in the process of reaching the highest status as regards Aujeszky’s disease in accordance to the plan referred to in point (2);

(iii) they have lived for at least 90 days before dispatch.

1. come from Member States or regions listed in Annex I; or

2. come from:

(a) Member States or regions listed in Annex II; and

(b) a holding which fulfils the requirements of Article 1(3); or

3. fulfil the following conditions:

(a) Aujeszky’s disease must be compulsorily notifiable in the Member State of origin;

(b) a plan for the control and eradication of Aujeszky’s disease is in place in the Member States or region of origin, which fulfils the criteria laid down in Article 1(2);

(c) no clinical, pathological or serological evidence of Aujeszky’s disease has been recorded in the previous 12 months in the holding of origin of the pigs in question;

(d) the pigs must have been isolated in accommodation approved by the competent authority for the 30 days immediately prior to movement and kept isolated in such a way that any risk of spreading of Aujeszky’s disease is prevented;

(e) the pigs must have been subjected, with negative results, to a serological test for the presence of gE antibodies. Sampling for the last test must be performed within 15 days prior to shipment. The number of pigs tested must be sufficient to detect 2 % seroprevalence with 95 % confidence in these pigs;

(f) the pigs must have lived in the holding of origin or in a holding of an equivalent status since birth, and have remained in the holding of origin for at least 90 days.

1. come from Member States or regions listed in Annex I; or

2. come from:

(a) Member States or regions listed in Annex II; and

(b) a holding which fulfils the requirements of Article 1(3); or

3. fulfil the following conditions:

(a) Aujeszky’s disease must be compulsorily notifiable in the Member State of origin;

(b) a plan for the control and eradication of Aujeszky’s disease is in place in the Member States or region of origin, which fulfils the criteria laid down in Article 1 point (2);

(c) no clinical, pathological or serological evidence of Aujeszky’s disease has been recorded in the previous 12 months in the holding of origin of the pigs in question;

(d) a serological survey for Aujeszky’s disease, demonstrating its absence and that vaccinated pigs have been free from gE antibodies, has been carried out in the holding of origin and between 45 and 170 days prior to shipment;

(e) the pigs must either have lived in the holding of origin since birth or have remained in such holdings for at least 30 days after introduction from a holding of an equivalent status, where a serological survey equivalent to the one referred to in point (d) has been carried out.

(a) the status of the holding and of the Member State or region of origin of the pigs in question as regards Aujeszky’s disease;

(b) in case the pigs are not originating from a Member State or a region free of the disease, the status of the holding and of the Member State or regions of destination for the pigs in question as regards Aujeszky’s disease;

(c) the compliance of the pigs in question with the conditions laid down in this Decision.

1. The institutes listed in paragraph 2(d) shall evaluate Elisa ADV-gE tests and kits against the criteria in paragraph 2(a), (b) and (c). The competent authority in each Member State shall ensure that only Elisa ADV-gE kits that meet these standards shall be registered. The examinations listed in 2(a) and (b) must be carried out prior to approval of the test and the examination in 2(c), at least, must thereafter be carried out on each batch.

2. Standardisation, sensitivity and specificity of the test.

(a) The sensitivity of the test must be of such a level that the following Community reference sera are scored positive:

— Community reference serum ADV 1 at 1:8 dilution,

— Community reference serum ADV-gE A,

— Community reference serum ADV-gE B,

— Community reference serum ADV-gE C,

— Community reference serum ADV-gE D,

— Community reference serum ADV-gE E,

— Community reference serum ADV-gE F.

(b) The specificity of the test must be of such a level that the following Community reference sera are scored negative:

— Community reference serum ADV-gE G,

— Community reference serum ADV-gE H,

— Community reference serum ADV-gE J,

— Community reference serum ADV-gE K,

— Community reference serum ADV-gE L,

— Community reference serum ADV-gE M,

— Community reference serum ADV-gE N,

— Community reference serum ADV-gE O,

— Community reference serum ADV-gE P,

— Community reference serum ADV-gE Q.

(c) For batch control, Community reference serum ADV 1 must be scored positive at 1:8 dilution and one of the Community reference sera from ADV-gE G to ADV-gE Q, as listed in point (b), must be scored negative.

(d) The institutes listed below will, in addition, be responsible for checking the quality of the ELISA method in each Member State, and in particular for producing and standardising national reference sera according to the Community reference sera.

1. Member State:

2. Date:

3. Reporting period:

4. Number of holdings where AD has been detected by means of clinical, serological or virological investigations:

5. Information on AD vaccination, serological investigations and categorisation of holdings (please complete the attached table):

6. Further information on serological monitoring in Artificial Insemination Centres, for export purposes, in the framework of other surveillance schemes, etc.: